Drug Profile
ASP 1361
Alternative Names: AAV-mVChR1; ASP-1361; Research programme: AAV-mVChR1 gene therapy - Astellas/CLINOLatest Information Update: 01 Jan 2021
Price :
$50
*
At a glance
- Originator Tohoku University
- Developer Astellas Pharma; CLINO Corporation
- Class
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Retinitis pigmentosa
Most Recent Events
- 10 Dec 2020 Preclinical trials in Retinitis pigmentosa in Japan (Parenteral), before December 2020
- 10 Dec 2020 Astellas Pharma plans to submit an IND application for Retinitis pigmentosa, in 2021
- 28 Mar 2020 No recent reports of development identified for research development in Retinitis-pigmentosa in Japan (Parenteral)